bioRxiv · 10.64898/2026.11.09.765248
Minor intron splicing restricts E2F transcription factor activity in RB-deregulated prostate cancer
Abstract
Castration-resistant prostate cancer with neuroendocrine differentiation (CRPC-NE) arises in RB1-mutated lineage plastic cells in response to androgen receptor (AR)-targeted therapies. RB1 loss leads to constitutive E2F activation and cylin-dependent kinase (CDK) inhibitor resistance, making it challenging to restrict E2F activity. A post-transcriptional node is that typical E2Fs contain a rare but highly conserved minor intron, processed by the minor spliceosome (MiS). In an in vivo CRISPR screen, we nominate the MiS as the strongest dependency, and U6atac correlates strongest with E2F transcriptional programs in a clinical CRPC cohort. U6atac depletion led to mis-splicing of typical E2Fs, cell cycle arrest, and translation of a minor intron-containing E2F1 isoform (E2F1-MIRI) as a pharmacodynamic biomarker. Combined E2F activator depletion, induced further neuroendocrine (NE) specification. U6atac depletion shifted NE identity along the ASCL1 axis without the secretory granule program, and induced cell-surface antigens including DLL3, nominating MiS inhibition as a combination partner for antigen-directed agents.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Thienger, P., Paassen, I., Maier, B., Wang, C., Dayan, D., Benjak, A., Fuchs, V., Lehner, M., Girardini, K., Rosenstock, C., Rodriguez, A., Brandt, L. P., Morrissey, C., Coleman, I., Augspach, A., Clarke, D., Gerstein, M., Kanadia, R. N., Rubin, M. A.. 2026-11-15. Minor intron splicing restricts E2F transcription factor activity in RB-deregulated prostate cancer. https://doi.org/10.64898/2026.11.09.765248
Cite the original work for its findings. Save a collection to share your selection of sources.